The importance of its semaglutide franchise – including newly approved obesity drug Wegovy – to Novo Nordisk A/S’s ongoing sales growth was apparent as the company laid out its financial performance for the first half of 2021; the various iterations of the drug comprise nearly a quarter of the firm’s sales, excluding Wegovy, which the firm reported is off to a strong launch.
Novo’s net sales rose 5% year over year (12% at constant exchange rates) to DKK66.8bn ($10.6bn), the firm reported 5 August. Insulin sales declined 5% globally to DKK28bn ($4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
